Across TCGA pan-cancer cohorts, SPRR2E Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPRR2E data layer compared with 20 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SPRR2E Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPRR2E expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, UCEC, and LIHC are the cancer types where SPRR2E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.198	0.768	.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	All	0.014	0.543	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.944	0.681	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SPRR2E tumor-vs-normal RNA expression · all SPRR2E data types